Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tizona Therapeutics currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution is handled by 1 distinct examiner and is located within 1 distinct art unit, which reflects a concentrated focus for the company's current patent activity. The presence of only 1 distinct art unit indicates that the pending technology is specialized within a specific biological classification.
The busiest examiner for the portfolio is HOPKINS, SAMANTHA LAKE, who is responsible for 1 pending office action. Because the company's current interaction with the patent office is limited to 1 distinct examiner, the prosecution strategy must be tailored to the specific feedback and prior art cited by this individual. With only 1 pending office action, the company's immediate success is tied to the examination style of this single examiner. This concentration means that the applicant does not have multiple pending matters to compare across different examiners or art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009686 | BISPECIFIC IMMUNE CELL ENGAGERS WITH BINDING SPECIFICITY FOR HLA-G AND ANOTHER ANTIGEN | HOPKINS, SAMANTHA LAKE | 85d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009686 | BISPECIFIC IMMUNE CELL ENGAGERS WITH BINDING SPECIFICITY FOR HLA-G AND ANOTHER ANTIGEN | HOPKINS, SAMANTHA LAKE | 85d |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18009686 | BISPECIFIC IMMUNE CELL ENGAGERS WITH BINDING SPECIFICITY FOR HLA-G AND ANOTHER ANTIGEN | HOPKINS, SAMANTHA LAKE | 1641 | §102§112Other | Non-Final OA | 85d | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial